News

Net profit of ERIS Lifesciences rose 200.10% to Rs 281.61 crore in the quarter ended March 2026 as against Rs 93.84 crore during the previous quarter ended March 2025. Sales rose 7.07% to Rs 752.29 crore in the quarter ended March 2026 as against Rs 702.60 crore during the previous quarter ended March 2025.For the full year,net profit rose 76.08% to Rs 619.52 crore in the year ended March 2026 as against Rs 351.84 crore during the previous year ended March 2025. Sales rose 8.18% to Rs 3114.89 crore in the year ended March 2026 as against Rs 2879.26 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales752.29702.60 7 3114.892879.26 8 OPM %36.2135.92 -35.9635.33 - PBDT228.98206.12 11 935.28804.33 16 PBT159.41128.87 24 655.78488.87 34 NP281.6193.84 200 619.52351.84 76 Powered by Capital Market - Live News

ERIS Lifesciences announced that the Board of Directors of the Company at its meeting held on 20 May 2026, inter alia, have recommended the interim dividend of Rs 7.21 per equity Share (i.e. 721%) , subject to the approval of the shareholders.

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 20 May 2026.

ERIS Lifesciences has allotted 24,396 equity shares under ESOP on 11 May 2026. The paid-up share capital of the Company accordingly stands increased from Rs 13,85,42,887/- (13,85,42,887 equity shares of Re 1/- each) to Rs 13,85,67,256/- (13,85,67,256 equity shares of Re 1/- each).

Eris Lifesciences has received affirmation in credit ratings for non convertible debentures and bank facilities at IND AA; Stable/ IND A1+ from India Ratings and Research. The company`s issuer rating has been affirmed at IND AA; Stable.